Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:April 2015
End Date:December 2018
Contact:Kristen Rushton
Email:krushton@myriad.com

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Treatment Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients (LUNG CARE Registry)

This registry is intended to measure the effect of myPlan Lung Cancer™ test has on
influencing treatment decisions of Oncologists when added to standard clinical-pathological
parameters in patients with early stage NSCLC.

The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003)
and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006).


Inclusion Criteria:

- Diagnosis of early stage non-small cell lung adenocarcinoma

- Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the
investigational site

- Resection of tumor within previous 2 months of enrollment

- ECOG performance of 0-2

- A minimum life expectancy of six months

Exclusion Criteria

- Previous myPlan Lung Cancer test performed

- Pre-operative radiation or chemotherapy for NSCLC

- Post-operative radiation or chemotherapy for NSCLC

- Enrollment in a separate clinical trial restricting treatment options

- Unable to provide informed consent
We found this trial at
1
site
Clinical Trial Facility in Orlando Florida
Orlando, Florida 32804
Principal Investigator: Tseng, MD
?
mi
from
Orlando, FL
Click here to add this to my saved trials